ATP7A and leukemia: Along similar lines of research, a BTK/MNK (Mitogen-Activated Protein Kinase Interacting Kinase) dual inhibitor was developed for lymphoma and leukemia (QL-X-138; Figure 7), which interestingly establishes covalent binding to BTK and a standard reversible binding to MNK [165].